



MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

ABN 14 106 340 667

FACTORY 7, 56 SMITH ROAD, SPRINGVALE, VICTORIA 3171, AUSTRALIA

Telephone: +61 3 9547 1888 Facsimile: +61 3 9547 0262

Web: www.medicaldev.com Email: mdi@medicaldev.com

ASX RELEASE

Manufacturing Licence issued for Gulf States

MVP today announced that the Executive Board of the Health Ministers' Council for the GCC States (Saudi Arabia, Kuwait, UAE, Bahrain, Oman and Qatar) has issued a Manufacturing Licence to MVP for its manufacturing facility located in Springvale, Melbourne. It has also secured further orders in the region.

MVP has been actively marketing Pentrox™ to leading Ambulance Services and Defence Forces in the GCC States for months. Whilst product interest is high, many of these institutions have indicated that a purchase decision is dependent on registration.

Registration Process in GCC countries

To market Pentrox™ in the GCC States, MVP is required to complete a two step registration process. The first (and most lengthy) process is the approval of MVP as a Manufacturer of Pentrox™. This process is now complete with the issue of a Manufacturing Licence. The second step, which is now underway, is the approval of our product, Pentrox™. MVP expects to have final product registration by September 2005.

Further orders in the GCC

Notwithstanding the need for registration, MVP today also announced that it has secured further pre registration orders for Pentrox™ from the Ambulance Service operated by Dubai Police and also from one of the leading hotel groups in the United Arab Emirates.

The order from Dubai Police is their second order for Pentrox™. Their first order, placed in October 2004, was successfully used within the Ambulance Service as well as by their Tsunami Relief Team despatched to Bandah Aceh, Indonesia in January. Pentrox™ is ideally suited for use in mass disaster situations like the tsunami in South East Asia.

The GCC Market

The GCC States have a combined population in excess of 35 million people; approximately double the population of Australia. They are affluent countries with well funded health sectors.

Further announcements

MVP expects to make further announcements before the end of the financial year regarding further developments in the Middle East and also in relation to trials being conducted in Australia.

Further Information:

Mr Chris Weaver
Chief Executive Officer
03 9547 1888

Mr David Williams
Chairman
0414 383 593